OptiBiotix Health PLC Appointment of goetzpartners securities Limited (2455D)
25 Junio 2019 - 01:01AM
UK Regulatory
TIDMOPTI
RNS Number : 2455D
OptiBiotix Health PLC
25 June 2019
OptiBiotix Health plc
("OptiBiotix")
Appointment of goetzpartners securities Limited
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skin care, announces the appointment
of goetzpartners securities Limited ("GPSL"). GPSL will provide
financial advisory services to OptiBiotix Health Plc including
sector specific equity research and investor support services.
These services will be provided in addition to the services
provided by OptiBiotix's current broker, finnCap, extending the
companies reach into European investment markets.
GPSL is a member of the goetzpartners group and a leading
pan-European investment banking and corporate broking firm
dedicated to the healthcare sector. GPSL bring together a wide
range of investment, research, and sector expertise, with the
group's global footprint, to advance the interests of clients in
the healthcare sector.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce the appointment of goetzpartners securities Limited. The
appointment is intended to improve international institutional and
family funds buy side access, particularly from within Europe, and
to provide expert research analysis which can be distributed to
specialist institutional investors around the world. With
OptiBiotix's products now being commercialised in over 30 countries
around the world this is a strategic step to broaden the Company's
investors base with the support of a leading pan-European
investment bank and research company specialising in heathcare and
technology."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 020 3897 6663
Brigitte de Lima
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPLLFFERTISFIA
(END) Dow Jones Newswires
June 25, 2019 02:01 ET (06:01 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024